Dr. Timothy Burns Appointed VP, Head of Solid Tumor Clinical Advancement at Actinium Pharmaceuticals
Table of Contents
Dr. Timothy Burns has joined Actinium Pharmaceuticals, Inc. as Vice President and Head of Solid Tumor Clinical Development, as announced in a LinkedIn post on December 2nd, 2023. This move signifies a return to the field of radioligand therapy,especially focusing on prostate cancer,echoing his earlier academic work at MD Anderson Cancer Center.
Background and Previous Experience
Prior to joining Actinium Pharmaceuticals, Dr. Burns held a position at iTeos Therapeutics, were he expressed gratitude for the collaborative surroundings and the opportunity to learn within the biotech ecosystem. He specifically thanked Dr. Christopher Logothetis and dr. Timothy Thompson for their mentorship and ongoing support throughout his career.
Dr. Burns’s career trajectory demonstrates a commitment to innovative cancer treatments. His time at iTeos Therapeutics provided valuable experience in scientific innovation within a high-risk environment, alongside a team he described as “smart, dedicated, and brave.”
Focus at Actinium Pharmaceuticals
At Actinium Pharmaceuticals,Dr. Burns will lead the clinical development of alpha radioligand therapies for metastatic castration-resistant prostate cancer (mCRPC). This focus represents a return to his roots, building upon his foundational research conducted during his time at MD Anderson Cancer Center.
Actinium Pharmaceuticals is dedicated to developing and delivering innovative radioligand therapies for advanced cancers with notable unmet medical needs.Radioligand therapy is a form of precision medicine that uses radioactive molecules to target and destroy cancer cells. Alpha radioligand therapies,in particular,deliver highly potent radiation directly to tumor cells,minimizing damage to surrounding healthy tissue.
about Actinium Pharmaceuticals
Actinium Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing targeted radioligand therapies for cancer. The company’s pipeline includes innovative therapies designed to address significant unmet needs in various cancer types. You can find more information about Actinium Pharmaceuticals on their official website.
Key Takeaways:
* Dr.timothy Burns has been appointed VP, Head of Solid Tumor Clinical Development at Actinium Pharmaceuticals.
* His focus will be on advancing alpha radioligand therapies for metastatic castration-resistant prostate cancer.
* Dr. Burns previously held a role at iTeos Therapeutics and received mentorship from Dr. Christopher Logothetis and dr. timothy Thompson.
* This appointment represents a return to his academic work at MD Anderson Cancer Center.
This appointment underscores the growing importance of radioligand therapies in the fight against cancer and highlights actinium Pharmaceuticals’ commitment to pioneering next-generation treatments for patients with limited options. Dr. Burns’s expertise and leadership will be instrumental in driving the development and clinical success of these potentially life-changing therapies.
Worth a look